Published in Ann Surg Treat Res on June 11, 2015
Vascular Complications of Cancer Chemotherapy. Can J Cardiol (2015) 0.79
Hallmarks of cancer and AU-rich elements. Wiley Interdiscip Rev RNA (2016) 0.78
Video-assisted thoracoscopic surgery lobectomy for lung cancer versus thoracotomy: a less decrease in sVEGFR2 level after surgery. J Thorac Dis (2016) 0.78
EGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models. PLoS One (2016) 0.77
Cancer: An Oxidative Crosstalk between Solid Tumor Cells and Cancer Associated Fibroblasts. Biomed Res Int (2016) 0.77
Vascular endothelial growth factor A: just one of multiple mechanisms for sex-specific vascular development within the testis? J Endocrinol (2015) 0.77
Use of single chain antibody derivatives for targeted drug delivery. Mol Med (2016) 0.75
NMR-based metabolomics Reveals Alterations of Electro-acupuncture Stimulations on Chronic Atrophic Gastritis Rats. Sci Rep (2017) 0.75
Developmental transcriptome analysis and identification of genes involved in formation of intestinal air-breathing function of Dojo loach, Misgurnus anguillicaudatus. Sci Rep (2016) 0.75
Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget (2016) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 18.69
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell (2005) 7.90
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev (2007) 4.46
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev (2000) 4.24
Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer (2007) 4.22
Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med (2004) 3.63
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33
Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther (2005) 3.28
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res (2009) 3.11
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res (1995) 3.11
Cancer without disease. Nature (2004) 2.65
Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res (2001) 2.47
VEGF as a therapeutic target in cancer. Oncology (2005) 2.41
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
Arachidonic acid as a bioactive molecule. J Clin Invest (2001) 2.37
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene (2005) 2.24
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer (2002) 2.12
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest (2000) 2.08
Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett (2012) 2.07
Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol (2003) 2.03
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res (2000) 2.02
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A (2001) 1.90
Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res (2001) 1.83
Oxygen sensors and angiogenesis. Semin Cell Dev Biol (2002) 1.82
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res (2000) 1.82
Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer (2006) 1.77
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol (2002) 1.76
All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res (2004) 1.65
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate (2005) 1.56
The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev (2000) 1.52
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer (2001) 1.47
Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ (2001) 1.47
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res (2003) 1.38
The role of HER2 in angiogenesis. Semin Oncol (2001) 1.33
Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res (2004) 1.30
Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res (1998) 1.29
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res (2002) 1.27
PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun (2003) 1.22
Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer (2003) 1.16
The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer (2001) 1.16
c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas (2005) 1.14
COX-2, VEGF and tumour angiogenesis. Surgeon (2009) 1.14
Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer (2003) 1.10
A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res (2002) 1.08
ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer (2002) 1.06
Evidence for a link between IGF-I and cancer. Eur J Endocrinol (2004) 1.05
VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res (2009) 1.03
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res (2002) 1.02
Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery (2002) 1.02
Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J (2008) 1.01
Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol (2001) 0.97
Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol (2001) 0.97
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res (2002) 0.96
The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer (2001) 0.93
The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int J Oncol (2000) 0.87
PDGF-BB induces MAP kinase phosphorylation and VEGF expression in neurofibroma-derived cultured cells from patients with neurofibromatosis 1. J Dermatol (2002) 0.82
Effect of p53 gene transfection on vascular endothelial growth factor expression in endometrial cancer cells. Exp Mol Pathol (2003) 0.76
[Non-small cell lung cancer: 1) Molecular-target therapy]. Nihon Naika Gakkai Zasshi (2003) 0.76
Detection of BRAF(V600E) Mutations in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-Time PCR: A Comparison with Direct Sequencing. Korean J Pathol (2012) 0.89
Survivin may be a Key Target for Oxaliplatin. J Korean Soc Coloproctol (2010) 0.75
Potentiation of biological effects of mesenchymal stem cells in ischemic conditions by melatonin via upregulation of cellular prion protein expression. J Pineal Res (2017) 0.75